Systemic therapies for operable breast cancer patients have improved outcomes and have
thus become standard treatments. Recently, new molecular target drugs and regimens are …

A proliferative marker, expressed as the percentage of cells in a cell cycle, has been
developed and used as a discriminant of more aggressive malignant phenotypes in early …

The optimal management of breast cancer (BC) presents challenges due to the
heterogeneous molecular classification of the disease. We performed survival analysis on a …

The eighth editions of the primary tumor, lymph node and metastasis classifications for
breast cancer issued by the American Joint Commission of Cancer and the Union for …

Breast cancer represents a heterogeneous group of tumors with varied morphologic and
biological features, behavior, and response to therapy. The present routine clinical …

Precision medicine is a strategy for disease treatment and prevention that considers
individual variability in genes, environment, and lifestyle. Historically, breast cancer has …

It is well‐known that estrogens immensely contribute to the progression of human breast
carcinoma, but their detailed molecular mechanisms remain largely unclear. In this study, we …

Accurate prediction of recurrence risk is of vital importance for tailoring adjuvant
chemotherapy for individual breast cancer patients. Although recurrence risk has been …

The aim of the present study was to evaluate the promoter methylation status of SEPT9_v2
in breast cancer and to detect this methylated gene in circulating tumor DNA (ctDNA) in …

Abstract Curebest™ 95GC breast (95GC) is a multigene classifier we developed for the
prognostic prediction of patients with estrogen receptor (ER)‑positive, human epidermal …